0GO Stock Chart & Stats
€0.03
€0.00(0.00%)
At close: 4:00 PM EDT
€0.03
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume21.77K
Average Volume (3M)N/A
Market Cap
€16.96M
Enterprise Value€4.01M
Total Cash (Recent Filing)€1.50M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-31.25
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,775,721,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.55
Price to Sales (P/S)523.56
P/FCF Ratio-3.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Nuvec PlatformNuvec gives N4 Pharma a defined technology platform that can be applied across multiple drug-delivery markets, including vaccines and oncology. If development and external collaboration progress, the platform could support several commercialization paths rather than relying on one single therapeutic product.
Debt-free Balance SheetHaving no debt reduces solvency and refinancing pressure while preserving flexibility during the company’s development stage. This structure avoids interest obligations and gives management more capacity to direct available resources toward research, partnerships and platform development as opportunities emerge.
Narrowing Cash OutflowsAlthough N4 Pharma remains cash-burning, the reduction in operating and free-cash-flow outflows versus 2023 indicates some improvement in cash discipline or spending intensity. If maintained, lower burn could extend financial runway and reduce the pace at which additional funding may be required.
Bears Say
Persistent UnprofitabilityDeep and recurring operating and net losses show that the current business is not economically self-sustaining. Margins substantially below zero indicate costs remain far above the revenue base, creating a durable execution challenge until products, partnerships or licensing generate materially larger income.
Ongoing Cash BurnPersistent negative operating and free cash flow means accounting losses are translating into actual cash consumption rather than being mainly non-cash charges. Continued development therefore depends on available funding and successful commercial progress, increasing the financial consequences of delays or setbacks.
Small, Volatile Revenue BaseA very small and fluctuating revenue base provides limited evidence of repeatable commercial traction and makes results difficult to forecast. The reported zero gross profit in 2025 further questions current revenue quality, while fixed development costs continue to overwhelm the top line.
N4 Pharma News
0GO FAQ
What was N4 Pharma PLC’s price range in the past 12 months?
N4 Pharma PLC lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is N4 Pharma PLC’s market cap?
N4 Pharma PLC’s market cap is €16.96M.
When is N4 Pharma PLC’s upcoming earnings report date?
N4 Pharma PLC’s upcoming earnings report date is Feb 24, 2027 which is in 115 days.
How were N4 Pharma PLC’s earnings last quarter?
N4 Pharma PLC released its earnings results on Sep 30, 2026. The company reported -€0.001 earnings per share for the quarter.
Is N4 Pharma PLC overvalued?
According to Wall Street analysts N4 Pharma PLC’s price is currently Overvalued.
Does N4 Pharma PLC pay dividends?
N4 Pharma PLC does not currently pay dividends.
What is N4 Pharma PLC’s EPS estimate?
N4 Pharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does N4 Pharma PLC have?
N4 Pharma PLC has 1,775,721,000 shares outstanding.
What happened to N4 Pharma PLC’s price movement after its last earnings report?
N4 Pharma PLC reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of N4 Pharma PLC?
Currently, no hedge funds are holding shares in DE:0GO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
N4 Pharma PLC
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Eco Animal Health
―
Chill Brands Group PLC
―
Mountfield
―
Provexis
―
Shield Therapeutics
―